Lipocine (LPCN) Competitors $6.08 +0.54 (+9.75%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends LPCN vs. LTRN, TNXP, CEMI, LPTX, DERM, TELO, RANI, NVCT, INMB, and ANVSShould you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include Lantern Pharma (LTRN), Tonix Pharmaceuticals (TNXP), Chembio Diagnostics (CEMI), Leap Therapeutics (LPTX), Journey Medical (DERM), Telomir Pharmaceuticals (TELO), Rani Therapeutics (RANI), Nuvectis Pharma (NVCT), INmune Bio (INMB), and Annovis Bio (ANVS). These companies are all part of the "medical" sector. Lipocine vs. Lantern Pharma Tonix Pharmaceuticals Chembio Diagnostics Leap Therapeutics Journey Medical Telomir Pharmaceuticals Rani Therapeutics Nuvectis Pharma INmune Bio Annovis Bio Lipocine (NASDAQ:LPCN) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability. Does the MarketBeat Community favor LPCN or LTRN? Lipocine received 335 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 75.00% of users gave Lantern Pharma an outperform vote while only 69.96% of users gave Lipocine an outperform vote. CompanyUnderperformOutperformLipocineOutperform Votes34769.96% Underperform Votes14930.04% Lantern PharmaOutperform Votes1275.00% Underperform Votes425.00% Do analysts recommend LPCN or LTRN? Lipocine currently has a consensus target price of $10.00, indicating a potential upside of 64.47%. Given Lipocine's stronger consensus rating and higher probable upside, research analysts clearly believe Lipocine is more favorable than Lantern Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Lantern Pharma 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders & institutionals believe in LPCN or LTRN? 9.1% of Lipocine shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 6.1% of Lipocine shares are held by company insiders. Comparatively, 7.3% of Lantern Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to LPCN or LTRN? In the previous week, Lipocine had 1 more articles in the media than Lantern Pharma. MarketBeat recorded 2 mentions for Lipocine and 1 mentions for Lantern Pharma. Lipocine's average media sentiment score of 0.00 beat Lantern Pharma's score of -0.79 indicating that Lipocine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Is LPCN or LTRN more profitable? Lipocine's return on equity of -38.58% beat Lantern Pharma's return on equity.Company Net Margins Return on Equity Return on Assets LipocineN/A -38.58% -35.28% Lantern Pharma N/A -46.40%-42.58% Which has more volatility & risk, LPCN or LTRN? Lipocine has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Which has preferable valuation and earnings, LPCN or LTRN? Lantern Pharma has lower revenue, but higher earnings than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipocine$500K65.06-$16.35M-$1.59-3.82Lantern PharmaN/AN/A-$15.96M-$1.65-1.97 SummaryLipocine beats Lantern Pharma on 10 of the 16 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Lipocine News Delivered to You Automatically Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPCN vs. The Competition Export to ExcelMetricLipocinePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.53M$7.02B$5.33B$8.52BDividend YieldN/A7.92%5.07%4.13%P/E Ratio-3.8212.35128.4016.13Price / Sales65.06396.051,491.7792.21Price / CashN/A47.4339.5634.18Price / Book1.595.604.765.07Net Income-$16.35M$153.56M$118.92M$225.46M7 Day Performance5.37%-1.46%-0.39%0.07%1 Month Performance40.42%15.32%6.06%3.93%1 Year Performance137.50%43.07%38.23%32.51% Lipocine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPCNLipocine1.5518 of 5 stars$6.08+9.7%$10.00+64.5%+137.5%$32.53M$500,000.00-3.8210News CoverageLTRNLantern Pharma0.9061 of 5 stars$3.31+6.1%N/A+25.5%$35.65MN/A-2.0120News CoveragePositive NewsGap DownTNXPTonix Pharmaceuticals3.6345 of 5 stars$0.14-6.7%$53.50+38,306.3%-99.1%$19.12M$7.77M0.00103News CoverageCEMIChembio DiagnosticsN/A$0.46flatN/A+0.0%$16.71M$48.34M-0.38337Analyst ForecastLPTXLeap Therapeutics3.1154 of 5 stars$3.74flat$10.40+178.1%+144.8%$95.74M$1.50M-1.8740Positive NewsGap UpDERMJourney Medical3.4208 of 5 stars$6.17+7.3%$9.38+51.9%N/A$127.89M$77.68M-308.5090Upcoming EarningsShort Interest ↓High Trading VolumeTELOTelomir PharmaceuticalsN/A$4.25+4.7%N/AN/A$125.84MN/A0.001RANIRani Therapeutics3.1546 of 5 stars$2.31+0.9%$11.71+407.1%+20.9%$122.30M$2.72M-1.96110Gap UpNVCTNuvectis Pharma1.8597 of 5 stars$6.41-14.2%$21.00+227.6%-30.3%$119.55MN/A-4.978High Trading VolumeINMBINmune Bio2.3312 of 5 stars$6.04+3.2%$20.00+231.1%-14.6%$119.35M$160,000.00-2.9310Short Interest ↑News CoverageGap UpANVSAnnovis Bio2.1869 of 5 stars$9.09-2.0%$32.17+253.9%+44.9%$118.62MN/A-1.783Short Interest ↑ Related Companies and Tools Related Companies LTRN Alternatives TNXP Alternatives CEMI Alternatives LPTX Alternatives DERM Alternatives TELO Alternatives RANI Alternatives NVCT Alternatives INMB Alternatives ANVS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LPCN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipocine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
